Electronic Healthcare Data Can Be Used With Caution In Observational Safety Studies, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidance advises investigators how to work around limitations of electronic healthcare data; agency does not advocate specific type of study design but notes advantages of new (incident) user design.
You may also be interested in...
Observational Studies Should Get Safe Harbor For Preregistering Protocols – Humana
Payors could get more faith in real world data – and sponsors might get more protections for disseminating them – if ISPOR/ISPE task force recommendations are adopted by industry and US FDA.
FDA’s Post-Market Pharmacoepidemiologic Study Guidance Is 3 Years Away
FDA told participants at a May 7 workshop that it plans to have draft guidance for conducting post-market pharmacoepidemiologic safety studies ready for review in fiscal 2010, with final guidance to be released a year later
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.